Topic resource collection
Approved comparison material connected to this topic.
6 resourcesRead both sides
KPV (lysine-proline-valine) Inhibits NF-κB inflammatory signaling; melanocortin receptor agonist Oral (enteric-coated) or subcutaneous 500 mcg 3x daily (oral); 200–300 mcg daily (subQ) Pilot human trial in IBD; animal models in c…
BPC-157 Nitric oxide pathway modulation; promotes smooth muscle relaxation and mucosal healing 250–500mcg per dose, 1–2× daily Subcutaneous or oral Preclinical rodent models strong; human case series limited, no RCTs Most studied…
BPC-157 Angiogenesis and mucosal repair VEGF receptor activation, nitric oxide signaling 10 mcg/kg–10 mg/kg daily Moderate. Multiple animal studies, no human RCTs Best studied for structural repair; oral bioavailability contested…
Before starting any peptide protocol, understand the trade-offs between compounds, administration routes, and dosing schedules. KPV NF-κB inhibition, cytokine suppression (TNF-α, IL-6) IBS-D, IBS-M 500 mcg/day Once daily (morning…
BPC-157 Tight junction repair, VEGF upregulation, mucosal healing IBS-D (diarrhea-predominant) 250–500 mcg subcutaneous twice daily Bacteriostatic water, 2–8°C storage, use within 28 days First-line for barrier dysfunction. Addre…
Before selecting a peptide protocol, understanding how each candidate differs in mechanism, administration, and evidence level prevents mismatched expectations. BPC-157 Nitric oxide modulation, VEGF upregulation, mucosal repair S…